

From: Liverpool-ECMC
Sent: 11 November 2019 10:42
To: Liverpool-ECMC
Subject: Liverpool ECMC Newsletter November 2019

LIVERPOOL ECMC NEWSLETTER NOVEMBER 2019



****REMINDER: PSGBI MEETING - 21-22/11/2019****

This is a reminder that the **45th Meeting of the Society of Great Britain and Ireland (PSGBI)** is taking place at the Metropolitan Cathedral, Liverpool, between the 21st and 22nd November 2019.

The programme this year covers clinical and basic science, including sessions focussed on early diagnosis of pancreatic cancer, translational biomarker research and novel trial design. The National HPB Nurse Group Meeting and 12th Annual Nutrition Symposium are also taking place in parallel to the main meeting.

Further details on the programme can be found here:
<https://www.psgbi.org/annual-meeting-2019/programme/>.

Registration can be completed online via the following link:
<https://www.psgbi.org/meeting-booking/45th-annual-meeting-2019/>.

LIVERPOOL ECMC EARLY PHASE TRIALS CLINIC IS OPEN



The ECMC Early Phase Trials Clinic is now open. This weekly clinic runs every Monday afternoon at the Clatterbridge Cancer Centre.

Patients who are potentially eligible and interested in participating in phase I and non-randomised phase II clinical trials can be referred to this clinic via the following email address: ccf-tr.ecmcreferrals@nhs.net.



NEW EARLY PHASE TRIAL OPEN - REPLIMUNE RP2

The **REPLIMUNE RP2** trial is now open for recruitment. This is a phase I trial of a novel oncolytic virus (which expresses an antiCTLA4 antibody like protein).

Patients with advanced solid tumours with **superficial / subcutaneous accessible lesions** will be enrolled into a dose escalation phase of two dose level cohorts. In the dose escalation portion, patients will receive up to 5 doses of RP2 given every two weeks.

KEY INCLUSION CRITERIA

- Patients with histologically or cytologically confirmed advanced or metastatic non-neurological solid tumours, who have progressed on standard therapy or cannot tolerate standard therapy, or for which there is no standard therapy preferred to enrolment in a clinical trial

- At least one measurable and injectable tumour of ≥ 1 cm in longest diameter (or shortest diameter for lymph nodes)
- ECOG performance status 0-1

Patients can be referred via ccf-tr.ecmcreferrals@nhs.net.

OPEN TRIALS

Please contact [Jennie Derham](#) for potential referral to these trials.

- Telephone: 0151 556 5443
- Mobile: 07554 416 293
- E-mail: ccf-tr.ecmcreferrals@nhs.net



ADVANCED SOLID TUMOURS

- **ACIT-1** – A Phase I clinical study to determine the optimal dose for the safe immune restoration and immune response of allogeneic cell immunotherapy (ACIT-1) in adult cancer patients – *All advanced solid tumours*.
- **REPLIMUNE RP1** – An Open-Label, Multicenter, Phase 2 Study of RPI in Combination with Nivolumab in Patients with Microsatellite Instability High or Mismatch Repair Deficient Tumors – *Melanoma, Non-Melanoma Skin Cancer, Urothelial Bladder Carcinoma*.
- **REPLIMUNE RP2** – An Open-Label, Multicenter, Phase 1 Study of RP2 as a Single Agent and in Combination with PD1 Blockade in Patients *with Solid Tumors*

BREAST

- **plasmaMATCH** – A multiple parallel cohort, non-randomised, open label, multi-centre phase IIa clinical trial aiming to provide proof of principle efficacy for designated targeted therapies in patients with advanced breast cancer where the targetable mutation is identified through ctDNA screening – *Advanced breast cancer*.

HEAD & NECK

- **Cambridge Brain Mets Trial 1** – A proof of principle phase 1b / randomised phase 2 study of afatinib penetration into cerebral metastases for patients

undergoing neurosurgical resection, both with and without prior low-dose, targeted radiotherapy – *Brain metastases from lung or breast primary*.

- **NICO** – Neoadjuvant and adjuvant nivolumab as Immune Checkpoint inhibition in oral cavity cancer – *squamous cell carcinoma of the oral cavity*.

HPB / UPPER GI

- **OUTREACH** – A First-in-Human, multi-centre, open-label, Phase 1 clinical study with RNA oligonucleotide drug MTL-CEBPA to investigate its safety and tolerability in patients with advanced liver cancer (OUTREACH) – Advanced liver cancer.
- **POLARIS** - Phase 1-2 Study of ADI-PEG 20 plus FOLFOX in Subjects with Advanced Gastrointestinal Malignancies Focusing on Hepatocellular Carcinoma - *Hepatocellular Carcinoma*

MELANOMA

- **CirculATING Tumour DNA gUided therapy Switch (CAcTUS)** – A parallel arm, biomarker driven, phase II feasibility trial to determine the role of circulating tumour DNA in guiding a switch between targeted therapy and immune therapy in patients with *advanced cutaneous melanoma*.

NON-CTIMPS

- **HYST** – Hypersensitivity Study: A Mechanistic Investigation into Drug and Chemical Induced Hypersensitivity Reactions
- **PRIMM** – Predicting Response to Immunotherapy for Melanoma with gut Microbiome and metabolomics (the PRIMM study)
- **PROACT** – Patient Reported Opinions About Clinical Tolerability
- **SMP-2** – The Cancer Research UK Stratified Medicine Programme: Pilot Study

[Find out more...](#)

EVENTS & JOB OPPORTUNITIES

EVENTS

- [PSGBI Annual Network Meeting \(NOVEMBER 2019\)](#)
- [ECMC Junior Investigator Network Group: Training the Next Generation \(FEBRUARY 2020\)](#)
- <https://www.ecmcnetwork.org.uk/events>

JOB OPPORTUNITIES

- [Research Technician \(GRADE 4\) – University of Liverpool](#)

CONTACT US

If you require any information which isn't on the newsletter please contact the Liverpool ECMC Team via [e-mail](#).

Copyright © 2019 Liverpool ECMC, All rights reserved.

Our mailing address is:

livecmc@liv.ac.uk